Fifth Third Bancorp Grows Stock Holdings in Catalyst Pharmaceuticals, Inc. $CPRX

Fifth Third Bancorp grew its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 4,708.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 28,368 shares of the biopharmaceutical company’s stock after acquiring an additional 27,778 shares during the period. Fifth Third Bancorp’s holdings in Catalyst Pharmaceuticals were worth $702,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of CPRX. Royal Bank of Canada raised its position in Catalyst Pharmaceuticals by 39.1% during the 1st quarter. Royal Bank of Canada now owns 213,469 shares of the biopharmaceutical company’s stock valued at $5,177,000 after purchasing an additional 60,040 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Catalyst Pharmaceuticals by 5.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 72,052 shares of the biopharmaceutical company’s stock worth $1,749,000 after buying an additional 3,800 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Catalyst Pharmaceuticals by 11.9% during the first quarter. Goldman Sachs Group Inc. now owns 3,135,473 shares of the biopharmaceutical company’s stock valued at $76,035,000 after buying an additional 333,100 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Catalyst Pharmaceuticals by 99.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 526,297 shares of the biopharmaceutical company’s stock valued at $12,763,000 after buying an additional 262,392 shares during the period. Finally, Intech Investment Management LLC raised its holdings in shares of Catalyst Pharmaceuticals by 6.5% during the first quarter. Intech Investment Management LLC now owns 70,087 shares of the biopharmaceutical company’s stock valued at $1,700,000 after acquiring an additional 4,261 shares in the last quarter. 79.22% of the stock is currently owned by hedge funds and other institutional investors.

Catalyst Pharmaceuticals Stock Performance

CPRX stock opened at $31.49 on Tuesday. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $19.05 and a fifty-two week high of $32.56. The business’s 50-day moving average is $31.39 and its two-hundred day moving average is $27.39. The company has a market cap of $3.86 billion, a price-to-earnings ratio of 18.10, a P/E/G ratio of 0.96 and a beta of 0.74.

Analysts Set New Price Targets

Several research firms recently weighed in on CPRX. Robert W. Baird cut shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 7th. Oppenheimer downgraded Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, May 7th. Zacks Research cut Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 18th. HC Wainwright downgraded Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $35.00 to $31.50 in a report on Thursday, May 28th. Finally, Weiss Ratings raised Catalyst Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, June 3rd. Two analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $32.00.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).